Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Out-licensing: 2012’s “In” Thing?

Executive Summary

Talk to any big pharma business development executive about dealmaking trends for more than 15 minutes and the word out-licensing is bound to crop up. But are major drugmakers moving beyond the rhetoric and actually giving up rights to individual assets that heretofore would have been deemed too valuable to merit out-licensing? An analysis by IN VIVO suggests yes – but with qualifications.

You may also be interested in...



Do China Start-ups Differ From The West?

During the annual ChinaBio conference in Shanghai, four top start ups – Ascletis, Aslan, BeiGene and Hua Medicine – discuss how their strategies in China differ from the traditional U.S. biotech model.

Do China Start-ups Differ From The West?

During the annual ChinaBio conference in Shanghai, four top start ups – Ascletis, Aslan, BeiGene and Hua Medicine – discuss how their strategies in China differ from the traditional U.S. biotech model.

Institutionalizing Externalization At Big Pharma – The Third Leg

The pharmaceutical industry has a hard time saying goodbye to strategic assets. In fact, it’s much more adept at welcoming new ones: diversification – either geographic or into areas beyond pure-play pharmaceuticals – has become commonplace. But pharma needs to overcome its entrenched resistance to asset externalization, which should become a critical third leg in its attempts to build long-term shareholder value. Strategic, almost biotech-like externalization strategies should move from a peripheral to a core part of pharma’s activities. Why haven’t they already been embraced?

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003752

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel